Literature DB >> 20688032

Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.

Rory O'Hanlon1, Agata Grasso, Michael Roughton, James C Moon, Susan Clark, Ricardo Wage, Jessica Webb, Meghana Kulkarni, Dana Dawson, Leena Sulaibeekh, Badri Chandrasekaran, Chiara Bucciarelli-Ducci, Ferdinando Pasquale, Martin R Cowie, William J McKenna, Mary N Sheppard, Perry M Elliott, Dudley J Pennell, Sanjay K Prasad.   

Abstract

OBJECTIVES: We investigated the significance of fibrosis detected by late gadolinium enhancement cardiovascular magnetic resonance for the prediction of major clinical events in hypertrophic cardiomyopathy (HCM).
BACKGROUND: The role of myocardial fibrosis in the prediction of sudden death and heart failure in HCM is unclear with a lack of prospective data.
METHODS: We assessed the presence and amount of myocardial fibrosis in HCM patients and prospectively followed them for the development of morbidity and mortality in patients over 3.1 +/- 1.7 years.
RESULTS: Of 217 consecutive HCM patients, 136 (63%) showed fibrosis. Thirty-four of the 136 patients (25%) in the fibrosis group but only 6 of 81 (7.4%) patients without fibrosis reached the combined primary end point of cardiovascular death, unplanned cardiovascular admission, sustained ventricular tachycardia or ventricular fibrillation, or appropriate implantable cardioverter-defibrillator discharge (hazard ratio [HR]: 3.4, p = 0.006). In the fibrosis group, overall risk increased with the extent of fibrosis (HR: 1.18/5% increase, p = 0.008). The risk of unplanned heart failure admissions, deterioration to New York Heart Association functional class III or IV, or heart failure-related death was greater in the fibrosis group (HR: 2.5, p = 0.021), and this risk increased as the extent of fibrosis increased (HR: 1.16/5% increase, p = 0.017). All relationships remained significant after multivariate analysis. The extent of fibrosis and nonsustained ventricular tachycardia were univariate predictors for arrhythmic end points (sustained ventricular tachycardia or ventricular fibrillation, appropriate implantable cardioverter-defibrillator discharge, sudden cardiac death) (HR: 1.30, p = 0.014). Nonsustained ventricular tachycardia remained an independent predictor of arrhythmic end points after multivariate analysis, but the extent of fibrosis did not.
CONCLUSIONS: In patients with HCM, myocardial fibrosis as measured by late gadolinium enhancement cardiovascular magnetic resonance is an independent predictor of adverse outcome. (The Prognostic Significance of Fibrosis Detection in Cardiomyopathy; NCT00930735).
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20688032     DOI: 10.1016/j.jacc.2010.05.010

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  250 in total

Review 1.  Left ventricular hypertrophy: The relationship between the electrocardiogram and cardiovascular magnetic resonance imaging.

Authors:  Ljuba Bacharova; Martin Ugander
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-11-04       Impact factor: 1.468

2.  MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors.

Authors:  Yasuo Amano; Mitsunobu Kitamura; Morimasa Takayama; Masaki Tachi; Shinichiro Kumita
Journal:  Int J Cardiovasc Imaging       Date:  2012-03-04       Impact factor: 2.357

Review 3.  Cardiomyopathies: focus on cardiovascular magnetic resonance.

Authors:  G Quarta; D M Sado; J C Moon
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

4.  Correlation between ECG abnormalities and cardiac parameters in highly trained asymptomatic male endurance athletes: evaluation using cardiac magnetic resonance imaging.

Authors:  Gunnar Erz; Stefanie Mangold; Erik Franzen; Claus D Claussen; Andreas M Niess; Christof Burgstahler; Ulrich Kramer
Journal:  Int J Cardiovasc Imaging       Date:  2012-06-22       Impact factor: 2.357

5.  Cardiomyopathies: Myocardial fibrosis assessed by CMR to predict events in HCM.

Authors:  Nina Ajmone Marsan; Jeroen J Bax
Journal:  Nat Rev Cardiol       Date:  2010-11       Impact factor: 32.419

6.  Clinical value of cardiovascular magnetic resonance in patients with MR-conditional pacemakers.

Authors:  Claire E Raphael; Vassilis Vassiliou; Francisco Alpendurada; Sanjay K Prasad; Dudley J Pennell; Raad H Mohiaddin
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-11-20       Impact factor: 6.875

Review 7.  Are There Deleterious Cardiac Effects of Acute and Chronic Endurance Exercise?

Authors:  Thijs M H Eijsvogels; Antonio B Fernandez; Paul D Thompson
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 8.  Heart failure in patients with normal coronary anatomy: diagnostic algorithm and disease pattern of various etiologies as defined by cardiac MRI.

Authors:  Ralf Wassmuth
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

9.  High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy.

Authors:  Yasuki Hen; Nobuo Iguchi; Haruhiko Machida; Kaori Takada; Yuko Utanohara; Tetsuya Sumiyoshi
Journal:  Heart Vessels       Date:  2012-10-25       Impact factor: 2.037

10.  Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.

Authors:  Ali J Marian; Yanli Tan; Lili Li; Jeffrey Chang; Petros Syrris; Manouchehr Hessabi; Mohammad H Rahbar; James T Willerson; Benjamin Y Cheong; Chia-Ying Liu; Neal S Kleiman; David A Bluemke; Sherif F Nagueh
Journal:  Circ Res       Date:  2018-03-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.